Terms: = Prostate cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Prognosis
96 results:
1. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response.
Ebrahimi N; Manavi MS; Faghihkhorasani F; Fakhr SS; Baei FJ; Khorasani FF; Zare MM; Far NP; Rezaei-Tazangi F; Ren J; Reiter RJ; Nabavi N; Aref AR; Chen C; Ertas YN; Lu Q
Cancer Metastasis Rev; 2024 Mar; 43(1):457-479. PubMed ID: 38227149
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
3.
Shen K; Yu M; Ji Y; Zhou X; Liu B; Zhang W; Su R; Qi J; Wang Q; Xue W
Prostate; 2023 Sep; 83(12):1167-1175. PubMed ID: 37189301
[TBL] [Abstract] [Full Text] [Related]
4. The Role of C-Reactive Protein in the prognosis of prostate cancer: A meta-Analysis.
Liu T; Zhuo L
J Environ Public Health; 2023; 2023():6222324. PubMed ID: 36776544
[TBL] [Abstract] [Full Text] [Related]
5. Salvage Radical prostatectomy for Recurrent prostate cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort.
Calleris G; Marra G; Benfant N; Rajwa P; Ahmed M; Abreu A; Cacciamani G; Ghoreifi A; Ribeiro L; Westhofen T; Tourinho-Barbosa R; Raskin Y; Veerman H; Albisinni S; Smith JA; Rouprêt M; Oderda M; Massari E; Persad R; Van Der Poel H; Joniau S; Sanchez-Salas R; Kretschmer A; Cathcart P; Gill I; Karnes RJ; Tilki D; Shariat SF; Touijer K; Gontero P
Eur Urol Focus; 2023 Jul; 9(4):645-649. PubMed ID: 36682962
[TBL] [Abstract] [Full Text] [Related]
6. Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
Chin CP; Smith WH; Cesaretti J; Terk M; Garden EB; Araya JS; Palese MA; Stock RG; Buckstein M
Urol Oncol; 2023 Jun; 41(6):296.e9-296.e16. PubMed ID: 36588020
[TBL] [Abstract] [Full Text] [Related]
7. Non-obstructive jaundice as paraneoplastic syndrome of prostate carcinoma: Systematic review of published cases.
Santandreu-Morales I; Redondo-Cerezo E; Martín-Enguix D
Med Clin (Barc); 2023 Mar; 160(5):206-212. PubMed ID: 36526448
[TBL] [Abstract] [Full Text] [Related]
8. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract] [Full Text] [Related]
9. Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis.
Alshalalfa M; Nguyen TT; Stopsack KH; Khan A; Franco I; Seldon C; Swami N; Jin W; Meiyappan K; Ton M; Venstrom JM; Dee EC; Mahal BA
Urol Oncol; 2023 Feb; 41(2):106.e17-106.e23. PubMed ID: 36400666
[TBL] [Abstract] [Full Text] [Related]
10. Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both.
Suresh N; Teramoto Y; Wang Y; Miyamoto H
Urol Oncol; 2022 May; 40(5):193.e7-193.e14. PubMed ID: 35410776
[TBL] [Abstract] [Full Text] [Related]
11. Identification and Validation of the Prognostic Impact of metastatic prostate cancer Phenotypes.
Labe SA; Wang X; Lehrer EJ; Kishan AU; Spratt DE; Lin C; Morgans AK; Ponsky L; Garcia JA; Garrett S; Wang M; Zaorsky NG
Clin Genitourin Cancer; 2022 Aug; 20(4):371-380. PubMed ID: 35383004
[TBL] [Abstract] [Full Text] [Related]
12. Variable roles of interleukin-17F in different cancers.
Mikkola T; Almahmoudi R; Salo T; Al-Samadi A
BMC Cancer; 2022 Jan; 22(1):54. PubMed ID: 35012470
[TBL] [Abstract] [Full Text] [Related]
13. Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance.
Hayashi T; Miyamoto T; Nagai N; Kawabata A
Sci Rep; 2021 Aug; 11(1):17157. PubMed ID: 34433857
[TBL] [Abstract] [Full Text] [Related]
14. The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis.
Cheng B; Ye S; Bai P
World J Surg Oncol; 2021 May; 19(1):160. PubMed ID: 34051809
[TBL] [Abstract] [Full Text] [Related]
15. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-met-FRA1 signaling.
Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
[TBL] [Abstract] [Full Text] [Related]
16. The Role of Radiotherapy Among Patients With prostate Ductal Adenocarcinoma.
Patel M; Bimali M; Howie C; McClain P; Mehta S; Harari M; Hans HS; Agarwal A; Pederson A; Maraboyina S; Kim T
Clin Genitourin Cancer; 2021 Feb; 19(1):e41-e50. PubMed ID: 33616071
[TBL] [Abstract] [Full Text] [Related]
17. The Long-Term Risks of metastases in Men on Active Surveillance for Early Stage prostate cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract] [Full Text] [Related]
18. [Diagnosis and treatment of gastric cancer with immediate double primary carcinoma].
Yao HB; Zhang RC; Hu JF; Zhao ZK; Shao QS
Zhonghua Yi Xue Za Zhi; 2020 Oct; 100(38):3001-3004. PubMed ID: 33086451
[No Abstract] [Full Text] [Related]
19. Hematologic parameters are not predictors of upgrading or treatment in a racially diverse prospective study of men with prostate cancer on active surveillance.
Shelton TM; Greenberg JW; Silberstein JL; Krane LS
Aging Male; 2020 Dec; 23(5):1400-1408. PubMed ID: 32500781
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced prostate cancer.
Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
[TBL] [Abstract] [Full Text] [Related]
[Next]
